Group 1 - The controllable nuclear fusion sector in A-shares experienced a significant surge, with the sector index rising over 4% and 30 stocks within the sector increasing in value [1][2] - Notable performers included Xue Ren Co., Ltd. (002639) and Rongfa Nuclear Power (002366), both hitting the daily limit up, while Chen Guang Medical (430300) saw an increase of over 26% [1][2] - The controllable nuclear fusion index reached 1476.66, reflecting a rise of 3.71% [2] Group 2 - The U.S. nuclear energy sector saw a collective surge in stock prices, which positively influenced Asian nuclear power stocks, leading to gains in the Hong Kong market [3][4] - The China General Nuclear Power Index (887716.WI) rose by 3.6%, while the Nuclear Power Index (884046.WI) increased by 2.32% [3][4] Group 3 - Recent developments in the nuclear energy sector indicate a critical phase in the construction of nuclear fusion experimental reactors, with significant progress expected [5] - The BEST reactor project has officially commenced assembly, aiming for completion by 2027, while the CRAFT reactor is projected to be completed by the end of 2025 [5] - The market anticipates a rapid development in the controllable nuclear fusion industry, with increased project tenders and commercialization efforts expected in 2025 [5]

据报道，崔某此前造谣东方甄选在文旅直播活动中，向贵州省政府部门收取高达七位数的宣传费。东方 甄选于2024年6月29日发布声明，澄清从未向政府收取宣传费，且一直坚持不向企业或商家收取坑位 费。但崔某并未停止侵权行为，继续发布侵权视频和不实言论。对此，东方甄选采取法律途径维权。 5月23日，东方甄选发布声明称，近日，就东方甄选与崔某网络侵权纠纷案，北京市第四中级人民法院 作出二审判决，驳回崔某上诉，维持一审原判。该判决为终审判决。根据判决，崔某须在抖音账号发布 并置顶道歉声明，向东方甄选赔礼道歉，并赔偿东方甄选36000元。东方甄选表示，针对恶意造谣、抹 黑的网络侵权行为，东方甄选将持续通过法律手段维护合法权益。 ...

Group 1 - The Hong Kong Stock Exchange plans to increase the trading limits for futures and options contracts on the Hang Seng Index, Hang Seng China Enterprises Index, and Hang Seng Tech Index, pending regulatory approval [1] - The proposed change is set to take effect on July 2, 2025 [1] - This adjustment aims to enhance market liquidity and trading flexibility for participants [1]

智通财经APP讯，和铂医药-B(02142)发布公告，辉瑞(集团的合作伙伴)将于2025年美国临床肿瘤学会 (ASCO)年会上发表同类首创靶向间皮素(MSLN)之抗体偶联药物 (ADC) MesoC2 (HBM9033/PF- 08052666)的首次人体1期临床研究设计。 MesoC2最初由公司全资附属公司诺纳生物(苏州)有限公司(诺纳生物)利用其专有的Harbour Mice平台及 一体化ADC平台自主研发，并于2023年12月通过全球许可协议授权予辉瑞。该ADC目前正在开展一项 针对多种晚期实体瘤患者的1期开放标签研究。 MesoC2在体外试验及异种移植模型中展示出显著的抗肿瘤疗效，并在食蟹猴中显示出可接受的安全性 特徵。 该项1期试验(NCT06466187)将按剂量递增、剂量优化和队列扩展开展，对最多365例患者进行评估 MesoC2的安全性、耐受性、药代动力学、药效动力学及基于RECIST v1.1标准的初步疗效。 摘要编号：TPS3163;展示形式：壁报;壁报编号：475a ;会议名称：壁报展示-新兴疗法-分子靶向药物与 肿瘤生物学 ;会议日期：2025年6月2日 展示核心要点： MesoC2是 ...

星展升六福集团目标价至21.03港元 评级"买入" 金十数据5月23日讯，星展发表研究报告指，由于近日市场波动，投资者因经济不确定因素上升而增持 黄金，而部分央行亦因全球能见度低以及对俄罗斯资产冻结的忧虑而买入更多黄金。市场预测至今年底 金价将上升超过10%。六福集团(00590.HK)受惠于不明朗时期潜在的黄金需求增长，3月底止末财季内 地零售收入按年增长1%，港澳地区则跌11%，较对上一季大幅改善。该行提到，六福轻资产模式有利 长远扩张，特别是中国内地低线城市。由于六福的黄金对冲亏损可能高于原先预期，星展对其今明两财 年的净利润预测分别下调11%和10%，维持"买入"评级，并延展估值基础至2026财年，以目标8倍市盈 率计，目标价由17.42港元上调至21.03港元。 ...

蔚来汽车(09866.HK)：5月25日19:30，新ET5 新ET5T将迎来上市发布。 ...

Group 1 - The core finding of the ASCO annual meeting is the announcement of the phase III clinical trial data for the "Defu Combination" (Bemarituzumab + Anlotinib) as a first-line treatment for locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC), showing a median progression-free survival (PFS) of 10.12 months, outperforming the comparative drug [1] - This study represents the first positive phase III clinical research result comparing immune checkpoint (PD-1) inhibitors combined with chemotherapy for the first-line treatment of squamous non-small cell lung cancer [1] - The innovative clinical trial design involved sequential treatment with Bemarituzumab combined with chemotherapy followed by Bemarituzumab combined with Anlotinib, breaking through traditional treatment standards [1] Group 2 - Based on the clinical research results, the company has submitted a new indication application for the "Defu Combination," which was accepted by the National Medical Products Administration (NMPA) on April 22 [2] - Anlotinib has already been approved for 8 indications, with 5 more in the NDA stage, while the "Defu Combination" has received approval for 3 indications and has 3 more in the new drug application stage [2] - The ASCO annual meeting is a highly regarded event in the clinical oncology field, serving as an industry benchmark, with over 70 original research projects from Chinese researchers selected for oral presentations this year, including many "First in Class" and "Best in Class" studies [2]

年轻人对头发健康管理的多样化需求持续推动着毛发医疗行业服务模式创新。近日，雍禾医疗集团与美团医药健康宣布 深化合作，双方将通过三大维度系统化合作，为用户提供"养固植"一站式毛发健康管理服务。 2024年，雍禾医疗在美团平台的交易用户数同比增长超20%。为应对市场变化，雍禾医疗与美团医药健康将重点探索线 上一站式产品服务体验、履约保障等服务升级。美团平台雍禾植发线上店在产品功能上进行改版，单一的植发养发服务 将升级为覆盖用户治疗全周期的产品服务。雍禾医疗相关负责人透露，美团医药健康拥有"到店""到家"全场景服务优 势，目前部分门店已打通美团线上买药场景；针对植发用户最为关注的手术效果不佳及门店医生选择困难等问题，双方 将进一步建设医生生态内容。 "近年来，美团买药购买生发、固发类药品用户显著增长，用户的毛发健康管理需求仍需得到进一步满足。此次深化合作 为的是探索新型产品服务及履约保障模式，打通美团买药与'到店'服务场景，为用户提供更好的一站式毛发健康管理体 验，助力毛发健康行业更好地发展。"美团医药健康相关负责人表示。 （文章来源：广州日报） 脱发成为困扰当代年轻人的"头"等大事。相关数据显示，脱发呈现年轻化趋 ...

5月23日早盘，港股医药生物板块强势领涨，恒生医疗保健指数截至发稿上涨1.69%，盘中一度涨逾 2.2%。 热门ETF中，恒生医疗指数ETF（159557）截至发稿上涨1.34%，成交额超1100万元，换手率超4%，交 投持续活跃。 成分股方面，绿叶制药涨超10%，海吉亚医疗、康哲药业涨超8%，亚盛医药-B、金斯瑞生物科技、信 达生物涨超5%。 消息面上，恒瑞医药拟在香港发行2.25亿股，今日挂牌交易，港股股价盘中一度涨超33%。 恒生医疗指数ETF（159557）标的指数为恒生医疗保健指数，该指数旨在反映恒生综合指数里主要经营 医疗保健业务成分股公司的表现。 广发证券表示，当前时刻建议重视港股创新药，原因如下： 3.政策及监管态度逐步转向对板块有利的情形。2023年下半年以来，政策层面出现了一系列积极信号， 标志着行业监管思路的调整，包括但不限于集采规则优化、创新药支持政策加码、医疗反腐常态化与纠 偏。 4.财务、估值及交易数据：营收增长、估值低位。财报层面：头部港股创新药公司受益于License-out放 量，营收和利润稳步增长。估值层面：医药板块相比于其他成长行业，估值处于相对安全的区间。 （本文机构观 ...

Group 1: Game Revenue Rankings - Tencent's "Honor of Kings" regained the top position in global mobile game revenue in April 2025, rising four places from the previous month [1][3] - "Last War: Survival" climbed to second place, benefiting from seasonal events like Easter [3] - "Whiteout Survival," "MONOPOLY GO!," and "Royal Match" ranked third to fifth, showcasing their consistent revenue generation capabilities [3] Group 2: Mobile Game Market Overview - Global mobile game player spending on App Store and Google Play reached approximately $6.48 billion in April 2025, a 4.5% decrease month-over-month [4] - The United States remains the largest mobile game market with revenues around $2 billion, accounting for 31.5% of total spending [4] - China (iOS) and Japan ranked second and third with 18.8% and 13.2% market shares, respectively [4] Group 3: Game Downloads Rankings - "Block Blast!" topped the global mobile game download chart in April 2025, followed by "ROBLOX," "Free Fire," "Subway Surfers," and "Ludo King" [5][8] - Global mobile game downloads reached 3.93 billion in April, reflecting an 8.4% decrease from the previous month [8] - India led in downloads with 739 million, representing 18.8% of the total, while the U.S. and Indonesia followed closely [8] Group 4: Notable Game Performances - "Honkai: Star Rail" saw a significant rise of 24 places in the rankings, driven by new character releases and popular events [4] - "Delta Force" achieved the highest download growth in April, ranking sixth overall, thanks to strong performances in the U.S. and Brazil [9] - New titles like "Cookingdom" and "Once Human" also performed well, indicating the importance of established gameplay and cross-platform adaptations in driving downloads [9]